Generic Drugs Market Poised to Garner Maximum Revenues During 2018 – 2026

1. Generic Drugs Market- GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2018-2026 © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Generic Drugs Market – Overview Generic drugs market growth is buoyed by increasing number of patented expiries for drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S and Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017 and 2020, which is expected to drive growth of the generic drugs market. Global generics market is highly competitive with many Asia Pacific companies entering the developed markets such as the U.S., Germany, France, and UK. Recent past has witnessed spurt in mergers and acquisitions between generic drug manufacturers, with major players focusing on enhancing their product portfolio through such inorganic strategies. For instance, Teva Pharmaceutical Industries Pvt. Ltd., Pfizer, Inc., Mylan, Sun Pharmaceutical, and Fresenius Kabi entered into acquisitions to increase their revenue share in the generic drugs market. Increase in number of competitor’s for generic drugs market put the pressure on manufacturers of pricing. Moreover, price celling actions by respective governments is further aggravating the profit margins of generic drug manufacturers. Considering the challenges of pricing pressure as generics outfits feel the pinch with thin margins, the market is expected to exhibit steady growth in the future. © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Competitive Analysis: Competitive Analysis: Teva Pharmaceuticals Industries strengthened its position in the generic drugs market through acquisition of the generic segment of Allergan, plc for US$ 40.5 billion in August 2016. This resulted in significant growth in revenue contribution of its generic drug segment, pegged at US$ 9.5 billion in 2016. growth in revenue contribution of its generic drug segment, pegged at US$ 9.5 billion in 2016. Teva Pharmaceuticals Industries strengthened its position in the generic drugs market through acquisition of the generic segment of Allergan, plc for US$ 40.5 billion in August 2016. This resulted in significant ● ● Mylan ranks second in the list of generic drug manufacturers, and this is due to the acquisition valued at US$ 7.2 Bn of Sweden’s Meda by Mylan, in year 2016. This also aided Mylan to increase its sales of over- the-counter drugs and expand its presence in new emerging markets such as China, Southeast Asia, Russia, and the Middle East. and the Middle East. Mylan ranks second in the list of generic drug manufacturers, and this is due to the acquisition valued at US$ 7.2 Bn of Sweden’s Meda by Mylan, in year 2016. This also aided Mylan to increase its sales of over- the-counter drugs and expand its presence in new emerging markets such as China, Southeast Asia, Russia, ● ● Sandoz—Novartis Group’s business segment dealing in generic medicines—reported rampant growth of 9% Y-o-Y in 2016, in sales volume, with revenue pegged at US$ 9 Bn. However, it was partially offset by a 6% erosion in price. Pfizer is at the fourth position (US$ 4.6 Bn revenue in 2016). Pfizer acquired Hospira in 2015, in order to increase its product portfolio of both generic and branded products. Pfizer offers over 220 injectable medications, plus other off-brand products, which is expected to aid in gaining high revenue in near future. Patent loss of Viagra in 2017, will lead to significant generic competition from Teva and Mylan. near future. Patent loss of Viagra in 2017, will lead to significant generic competition from Teva and Mylan. Sandoz—Novartis Group’s business segment dealing in generic medicines—reported rampant growth of 9% Y-o-Y in 2016, in sales volume, with revenue pegged at US$ 9 Bn. However, it was partially offset by a 6% erosion in price. Pfizer is at the fourth position (US$ 4.6 Bn revenue in 2016). Pfizer acquired Hospira in 2015, in order to increase its product portfolio of both generic and branded products. Pfizer offers over 220 injectable medications, plus other off-brand products, which is expected to aid in gaining high revenue in ● ● Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1084 Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1084 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Generic Drugs Market: Key Players TEVA PHARMACEUTICAL INDUSTRIES ● MYLAN N.V. ● NOVARTIS INTERNATIONAL AG. ● PFIZER, INC.. ● ALLERGAN PLC. ● SUN PHARMACEUTICALS. ● FRESENIUS KABI. ● ENDO INTERNATIONAL. ● LUPIN LIMITED ● SANOFI ● View this report @ https://www.coherentmarketinsights.com/ongoing-insight/generic-drugs-market-global-competitive-analysis-1084 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT COHERENT MARKET INSIGHTS SECTOR COVERAGE Healthcare CLINICAL DIAGNOSTIC HEALTHCARE IT PHARMACEUTICAL MEDICAL IMAGING MEDICAL DEVICES Chemicals & Materials Speciality and Fine Chemicals Advanced Materials Bulk Chemicals Green Chemicals Polymers & Resins Food Ingredients Cosmetic Ingredients © Coherent market Insights. All Rights Reserved

7. ABOUT COHERENT MARKET INSIGHTS KEY STATS RESEARCH SOLUTIONS GLOBAL REPORTS FEASIBILITY STUDIES 100+ Insights Published Per Year CUSTOMIZED SOLUTIONS COUNTRY ANALYSIS 150+ CONSULT PROJECTS Consulting Projects Till Date SURVEY RESEARC H EXCEL FORECAST DATABASE 125+ COMPETITIVE ASSESSMENT Clients Worldwide Per Year 110+ TECHNOLOGY SNIPPETS Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com THANK YOU For other queries contact: Mr. Shah (M anager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved